Literature DB >> 20644094

Tumor-host interactions: a far-reaching relationship.

Sandra S McAllister1, Robert A Weinberg.   

Abstract

Carcinomas are composed of neoplastic epithelial cells, which form the heart of the tumor, as well as a variety of mesenchymal cell types and extracellular matrix components that comprise the tumor stroma, often termed its microenvironment. The normal counterparts of some stromal cells are thought to limit tumor growth, while tumor-associated stromal cells have been convincingly shown to actively promote tumor progression via complex heterotypic interactions with the nearby carcinoma cells. More recent advances have revealed that tumor-host interactions extend well beyond the local tissue microenvironment (ie, interactions between the neoplastic cells and the nearby stroma) and that tumors not only respond to, but actively perturb host organs at distant anatomic sites. This indicates that many aspects of tumor biology can only be explained by a detailed understanding of both local and systemic interactions, yet we currently have only a fragmentary understanding of both processes. In this review, we address the recent advances in our understanding of the contributions of local and systemic environments to cancer progression, the ability of tumors to actively perturb the host environment, and current therapeutic approaches that are designed to disrupt tumor-host relationships.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644094     DOI: 10.1200/JCO.2010.28.4257

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  141 in total

1.  Host-derived pericytes and Sca-1+ cells predominate in the MART-1- stroma fraction of experimentally induced melanoma.

Authors:  J Humberto Treviño-Villarreal; Douglas A Cotanche; Rosalinda Sepúlveda; Magda E Bortoni; Otto Manneberg; Taturo Udagawa; Rick A Rogers
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

2.  Perspectives on personalized cancer care.

Authors:  Garrett M Dancika; Dan Theodorescu
Journal:  Urol Oncol       Date:  2012 Mar-Apr       Impact factor: 3.498

3.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

4.  Expression of Periostin in Cancer-associated Fibroblasts in Mammary Cancer in Female Dogs.

Authors:  Paulina Borecka; Katarzyna Ratajczak-Wielgomas; Rafal Ciaputa; Małgorzata Kandefer-Gola; Izabela Janus; Aleksandra Piotrowska; Alicja Kmiecik; Marzena Podhorska-Okolów; Piotr Dzięgiel; Marcin Nowak
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 5.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

6.  Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures.

Authors:  Cui Li; Hong T Nguyen; Yan Zhuang; Zhen Lin; Erik K Flemington; Ying Zhuo; Stephen P Kantrow; Gilbert F Morris; Deborah E Sullivan; Bin Shan
Journal:  Gene       Date:  2012-10-02       Impact factor: 3.688

7.  Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.

Authors:  Julie Lecomte; Anne Masset; Silvia Blacher; Ludovic Maertens; André Gothot; Marie Delgaudine; Françoise Bruyère; Oriane Carnet; Jenny Paupert; Martin Illemann; Jean-Michel Foidart; Ida K Lund; Gunilla Høyer-Hansen; Agnes Noel
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?

Authors:  Yoo Jin Lee; Byoung Kuk Jang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

9.  MRI can be used to assess advanced T-stage colon carcinoma as well as rectal carcinoma.

Authors:  Akitoshi Inoue; Shinichi Ohta; Norihisa Nitta; Masahiro Yoshimura; Tomoharu Shimizu; Masaji Tani; Ryoji Kushima; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2016-10-18       Impact factor: 2.374

10.  Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.

Authors:  Michael J Flister; Shirng-Wern Tsaih; Alexander Stoddard; Cody Plasterer; Jaidip Jagtap; Abdul K Parchur; Gayatri Sharma; Anthony R Prisco; Angela Lemke; Dana Murphy; Mona Al-Gizawiy; Michael Straza; Sophia Ran; Aron M Geurts; Melinda R Dwinell; Andrew S Greene; Carmen Bergom; Peter S LaViolette; Amit Joshi
Journal:  Breast Cancer Res Treat       Date:  2017-05-31       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.